DrugPatentWatch Database Preview

Celgene Company Profile

CELGENE has seven approved drugs.

There are forty-eight US patents protecting CELGENE drugs.

There are six hundred and seventy-five patent family members on CELGENE drugs in fifty-one countries and twenty-five supplementary protection certificates in twelve countries.

International Patents:	675
US Patents:	48
Tradenames:	7
Ingredients:	7
NDAs:	7
Patent Litigation for Celgene:	See patent lawsuits for Celgene
PTAB Cases with Celgene as patent owner:	See PTAB cases with Celgene as patent owner

Subscribe to access the full database, or request a copy of the full page.
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-004	Jun 29, 2006		RX	Yes	Yes	8,315,886	See Pricing				See Pricing
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014		RX	Yes	No	9,872,854	See Pricing				See Pricing
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-002	Jan 17, 2003		RX	Yes	No	7,959,566	See Pricing				See Pricing
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-001	Dec 27, 2005		RX	Yes	No	8,404,717	See Pricing				See Pricing
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-004	Jun 29, 2006		RX	Yes	Yes	7,189,740	See Pricing				See Pricing
Celgene	POMALYST	pomalidomide	CAPSULE;ORAL	204026-002	Feb 8, 2013		RX	Yes	No	8,828,427	See Pricing	Y	Y		See Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or request a copy of the full page.
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-004	Jan 10, 2007	8,204,763	See Pricing
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-003	Jun 29, 2006	8,288,415	See Pricing
Celgene	POMALYST	pomalidomide	CAPSULE;ORAL	204026-004	Feb 8, 2013	8,204,763	See Pricing
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-003	Jan 17, 2003	7,435,745	See Pricing
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-001	Jul 16, 1998	6,561,976	See Pricing
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-004	Jan 10, 2007	6,561,976	See Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	1 mg, 2 mg, 3 mg and 4 mg	➤ Subscribe	2017-02-08
➤ Subscribe	Capsules	5 mg, 10 mg and 15 mg	➤ Subscribe	2010-08-30
➤ Subscribe	Capsules	50 mg and 100 mg	➤ Subscribe	2006-12-18
➤ Subscribe	Capsules	150 mg	➤ Subscribe	2014-02-03
➤ Subscribe	Tablets	10 mg, 20 mg and30 mg	➤ Subscribe	2018-03-22
➤ Subscribe	Capsules	25 mg	➤ Subscribe	2010-07-12
➤ Subscribe	Capsules	2.5 mg and 20 mg	➤ Subscribe	2016-07-12
➤ Subscribe	Capsules	200 mg	➤ Subscribe	2006-09-25
➤ Subscribe	Injection	10 mg/vial	➤ Subscribe	2013-11-05

Subscribe to access the full database, or request a copy of the full page.
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0925294	07C0056	France	See Pricing	PRODUCT NAME: LENALIDOMIDE; REGISTRATION NO/DATE: EU/1/07/391/001-004 20070618
0688211	SPC/GB08/039	United Kingdom	See Pricing	PRODUCT NAME: THALIDOMIDE (INTERNATIONAL NON-PROPRIETARY NAME) 2-(2,6-DIOXOPIPERIDIN-3-YL) ISOINDOLINE-1,3-DIONE (SYSTEMATIC (IUPAC) NAME); REGISTERED: UK EU/1/08/443/001 20080416
0688211	08C0036	France	See Pricing	PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416
2105135	122015000013	Germany	See Pricing	PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE (IMNOVID); REGISTRATION NO/DATE: EU/1/13/850 20130805
0925294	56/2007	Austria	See Pricing	PRODUCT NAME: 1-OXO-2(2,6-DIOXOPIPERIDIN-3-YL)-4- AMINOISOINDOLIN, AUCH 3-(4'AMINOISOINDOLIN-1'-ON)- 1-PIPERIDIN-2,6DION GENANNT, GEGEBENENFALLS IN FORM EINES SAEUREADDITIONSSALZES; REGISTRATION NO/DATE: EU/1/07/391/001 - EU/1/07/391/004 20070614
2105135	C300717	Netherlands	See Pricing	PRODUCT NAME: POMALIDOMIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN, SOLVATEN, HYDRATEN OF STEREOISOMEREN DAARVAN; REGISTRATION NO/DATE: EU/1/13/850 20130805
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.